• Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY (paltusotine), the first once-daily oral SST2 agonist, for treating adult acromegaly across the EU and EEA, based on Phase 3 PATHFNDR data showing biochemical and symptom control with a generally well-tolerated safety profile.
• This approval, coupled with PALSONIFY’s Orphan Drug Designation in the EU and initial commercialization plans in Germany and Austria, expands Crinetics’ addressable acromegaly market beyond the U.S. and supports its efforts to shift treatment toward oral therapies.
• Now we’ll examine how EU-wide approval of PALSONIFY, the first once-daily oral acromegaly therapy, may reshape Crinetics’ investment narrative.

Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

Crinetics Pharmaceuticals Investment Narrative Recap

To own Crinetics, you need to believe PALSONIFY can anchor a global acromegaly franchise while the broader endocrine pipeline matures despite ongoing losses. EU approval broadens the addressable market and supports the oral-therapy story, but it does not change the near term reality that the key catalyst remains launch execution and prescription growth, while the biggest risk is heavy cash use against still-limited product revenue and the potential need for future dilution.

Among recent updates, the most relevant alongside EU approval is Crinetics’ multiple capital raises, including a US$350.1 million follow on offering in January 2026. This bolsters a cash balance of about US$1.1 billion, which the company expects to fund operations into 2029 as it commercializes PALSONIFY and advances late stage trials. That financial cushion may help the company absorb slower than hoped early uptake or setbacks in its pipeline while investors watch launch metrics closely.

Yet even with global approvals progressing, investors should be aware that payer behavior and reimbursement decisions could still...

Crinetics Pharmaceuticals' narrative projects $454.3 million revenue and $94.8 million earnings by 2029. This implies 566.4% yearly revenue growth and an earnings increase of about $518 million from current earnings of -$423.1 million.

Uncover how Crinetics Pharmaceuticals' forecasts yield a $82.43 fair value, a 111% upside to its current price.

Exploring Other Perspectives

Before this EU approval, the most optimistic analysts were modeling revenue to grow over 600 percent annually and reach about US$534.2 million by 2028, which assumes fast, broad PALSONIFY uptake and contrasts with more cautious views that highlight payer tightening and a structurally limited acromegaly market, so it is worth asking how this new EU decision might shift those expectations.

Explore 4 other fair value estimates on Crinetics Pharmaceuticals - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Crinetics Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Crinetics Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.